

## THE UNIVERSITY of EDINBURGH

### Edinburgh Research Explorer

# Longitudinal metabolic profiling of maternal obesity, gestational diabetes and hypertensive pregnancy disorders

#### Citation for published version:

Kivelä, J, Sormunen-harju, H, Girchenko, PV, Huvinen, E, Stach-lempinen, B, Kajantie, E, Villa, PM, Reynolds, RM, Hämäläinen, EK, Lahti-pulkkinen, M, Murtoniemi, KK, Laivuori, H, Eriksson, JG, Räikkönen, K & Koivusalo, SB 2021, 'Longitudinal metabolic profiling of maternal obesity, gestational diabetes and hypertensive pregnancy disorders', *Journal of Clinical Endocrinology & Metabolism*. https://doi.org/10.1210/clinem/dgab475

#### **Digital Object Identifier (DOI):**

10.1210/clinem/dgab475

#### Link: Link to publication record in Edinburgh Research Explorer

**Document Version:** Peer reviewed version

Published In: Journal of Clinical Endocrinology & Metabolism

#### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

#### Take down policy

The University of Édinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



#### Longitudinal metabolic profiling of maternal obesity, gestational diabetes and

#### hypertensive pregnancy disorders

Ms. Jemina KIVELÄ\*; Helsinki, Finland; Department of Obstetrics and Gynecology, University of Helsinki, Helsinki University Hospital and Department of Public Health, Helsinki, Finland

Ms. Heidi SORMUNEN-HARJU\*; Helsinki, Finland; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Dr. Polina V GIRCHENKO; Helsinki, Finland; Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Dr. Emilia HUVINEN; Helsinki, Finland; Teratology Information Service, Emergency Medicine, Department of Prehospital Emergency Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Dr. Beata STACH-LEMPINEN; Lappeenranta, Finland; Department of Obstetrics and Gynecology, South Karelia Central Hospital, Lappeenranta, Finland

Prof. Eero KAJANTIE; Helsinki, Finland; PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Oulu Finland; Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki and Oulu, Finland; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Dr. Pia M VILLA; Helsinki, Finland; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, Hyvinkää Hospital at Helsinki and Uusimaa Hospital District, Hyvinkää, Finland

Dr. Rebecca M REYNOLDS; Edinburgh, United Kingdom; Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom

Prof. Esa K HÄMÄLÄINEN; Kuopio, Finland; Department of Clinical Chemistry, University of Eastern Finland, Kuopio, Finland

Dr. Marius LAHTI-PULKKINEN; Helsinki, Finland; Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Finnish National Institute for Health and Welfare, Helsinki, Finland;

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ms. Katja K MURTONIEMI; Helsinki, Finland; Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland ja Department of Obstetrics

Dr. Hannele LAIVUORI; Helsinki, Finland; Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki. Finland; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland; Department of Obstetrics and Gynecology, Tampere University Hospital and Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland

and Gynaecology, University of Turku and Turku University Hospital, Turku, Finland

Prof. Johan G ERIKSSON; Helsinki, Finland; Singapore Institute for Clinical Sciences, Agency for Science Technology and Research, Singapore, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Department of General Practice and Primary Health Care, University of Helsinki, Finland, Folkhälsan Research Center, Helsinki, Finland

Katri RÄIKKÖNEN\*\*; Helsinki, Finland; Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Saila B KOIVUSALO<sup>\*\*</sup>; Helsinki, Finland; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

\* co-corresponding authorship

\*\* shared group leadership / PI

Corresponding authors and reprint requests:

Jemina Kivelä, Kaarlo Sarkian katu 7 A 2, 02600 Espoo, Finland, jemina.kivela@hus.fi, +358 408375363, ORCID 0000-0002-0605-8778

Heidi Sormunen-Harju, Mankkaanpuro 18A, 02180 Espoo, Finland, <u>heidi.sormunen-harju@hus.fi</u>,+358 405603977, ORCID 0000-0002-1038-4672



#### Sources of Support:

The PREDO project has been supported by EVO research funding (A special Finnish state subsidy for health science research), Academy of Finland, Signe and Ane Gyllenberg Foundation, Sigrid Juselius Foundation, University of Helsinki Research Funds, Finnish Medical Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Jane and Aatos Erkko Foundation, and Päivikki and Sakari Sohlberg Foundation. The RADIEL project has been supported by the Alfred Kordelin Foundation, Juho Vainio Foundation, Ahokas Foundation, the Finnish Foundation for Cardiovascular Disease, Special state subsidy for health science research of Helsinki University Hospital (HUH), Samfundet Folkhälsan, Finska Läkaresällskapet, Viipuri Tuberculosis Foundation, The Finnish Diabetes Research Foundation. RR acknowledges the support of the British Heart Foundation (RE/18/5/34216).

Disclosure summary:

The authors report no conflict of interest.

cei

#### Abstract

#### Context

Comprehensive assessment of metabolism in maternal obesity and pregnancy disorders can provide information about the shared maternal-fetal milieu and give insight into both maternal long-term health and intergenerational transmission of disease burden.

#### Objective

To assess levels, profiles and change in the levels of metabolic measures during pregnancies complicated by obesity, gestational diabetes (GDM) or hypertensive disorders.

#### **Design, Setting and Participants**

A secondary analysis of two study cohorts, PREDO and RADIEL, including 741 pregnant women.

#### **Main Outcome Measures**

We assessed 225 metabolic measures by nuclear magnetic resonance in blood samples collected at median 13 (interquartile range, 12.4-13.7), 20 (19.3-23.0) and 28 (27.0-35.0) weeks of gestation.

#### Results

Across all three time points women with obesity (body mass index, BMI≥30kg/m<sup>2</sup>) in comparison to normal weight (BMI 18.5-24.99 kg/m<sup>2</sup>) had significantly higher levels of most very-low-densitylipoprotein-related measures, many fatty and most amino acids and more adverse metabolic profiles. The change in the levels of most metabolic measures during pregnancy was smaller in obese than in normal weight women. GDM, preeclampsia and chronic hypertension were associated with metabolic alterations similar to obesity. The associations of obesity held after adjustment for GDM and hypertensive disorders, but many of the associations with GDM and hypertensive disorders were rendered non-significant after adjustment for BMI and the other pregnancy disorder.

#### Conclusions

This study shows that the pregnancy-related metabolic change is smaller in women with obesity, who display metabolic perturbations already in early pregnancy. Metabolic alterations of obesity and pregnancy disorders resembled each other suggesting a shared metabolic origin.

Keywords: Diabetes, Gestational; Hypertension, Gestational; Metabolomics; Nuclear Magnetic Resonance, Biomolecular; Pre-Eclampsia; Pregnancy; Pregnant women

#### Introduction

Maternal obesity complicates an increasing number of pregnancies. In 2016, globally 40% of women were overweight (body mass index, BMI, 25-29.99 kg/m<sup>2</sup>) and 15% obese (BMI $\ge$ 30 kg/m<sup>2</sup>) <sup>1</sup>. In less than five years, the number of women with obesity is estimated to rise by one third to over 21% <sup>2</sup>. Maternal overweight and obesity during pregnancy not only increase the mother's risk for gestational diabetes (GDM), hypertensive disorders and delivery complications <sup>3</sup>, but also the offspring's risk for preterm birth, intrauterine growth restriction, macrosomia and other perinatal complications, as well as obesity, metabolic disorders and neurodevelopmental impairment in childhood and later life <sup>4</sup>.

While the underlying mechanisms mediating the adverse effects of maternal obesity on the offspring still remain unknown, recent studies have implicated that perturbations in the maternal metabolome during pregnancy may play a role <sup>5, 6</sup>. A series of studies have shown that higher prepregnancy BMI, GDM and preeclampsia (PE) are associated with alterations in blood or urinary metabolome, including several lipoprotein-related variables, triglycerides, specific amino acids (AA), fatty acids (FA), and inflammatory markers <sup>7-10</sup>. These studies are, however, limited by having measured maternal metabolic profile at only one time-point during pregnancy or they have pooled metabolome data across trimesters. Normal pregnancy is associated with profound changes in the maternal metabolism to meet the physiological demands imposed by the pregnancy and to ensure adequate growth and development of the fetus <sup>11</sup>. Yet, it remains unknown if maternal overweight and obesity, GDM and hypertensive disorders induce changes in the maternal metabolic signatures above and beyond to that induced by the pregnancy in itself. Studying changes in the maternal metabolome profiles during pregnancy may help to identify novel biomarkers for therapeutic targets and critical time windows for preventive measures, and potential pathways that underpin the intergenerational transmission of metabolic adversities.

Against this background, the aim of this study was to assess if maternal prepregnancy overweight and obesity, GDM and hypertensive disorders were associated with alterations in the levels and profiles of metabolic measures and in change in the levels across three serial time points during pregnancy in two Finnish studies comprising 741 pregnant women. We used targeted highthroughput proton nuclear magnetic resonance (NMR)-based metabolomics interrogating 225 metabolic measures.

#### **Subjects**

The study population came from two Finnish studies: the Prediction and Prevention of Pre-eclampsia and Intrauterine Growth Restriction (PREDO) study <sup>12</sup> and the Finnish Gestational Diabetes Prevention (RADIEL) study <sup>13</sup>. The flowchart is presented as Figure 1.

The PREDO study enrolled 1,079 pregnant women between 12-14 weeks of gestation from 10 hospitals. Details of the enrollment are presented in Figure 1. Of the 404 women giving blood samples, a subgroup with second degree diastolic notch in the uterine blood flow were randomized to receive low-dose aspirin (n=61) or placebo (n=60) for preventing PE. Women providing blood samples in the PREDO cohort were younger (32.5 vs. 33.6 years, p=0.007) and less likely to be obese (29.1% vs. 39.3%, p=0.003) than women who did not.

RADIEL study enrolled 720 women in a randomized, controlled trial, to prevent GDM by lifestyle intervention among high-risk women (prior GDM and/or prepregnancy obesity) planning a pregnancy or in the first half of pregnancy (before 20 weeks of gestation). Of the 337 women giving blood samples, 177 were randomized in the intervention group receiving advice on diet and physical activity and 160 in the control group (standard care). In the RADIEL cohort the women providing blood samples were less likely to be obese (14.0% vs 20.5%, p=0.04) and have GDM (27.9% vs. 73.2%, p<0.0001) or PE (7.0% vs, 3.3%, p=0.04) than women who did not.

All study participants signed informed consent and the study protocols were approved by ethics committees of the Helsinki and Uusimaa Hospital District.

#### Methods

Metabolic profiling using the NMR platform

In both cohorts, venous blood samples were drawn from the antecubital vein between 7-10 AM after at least a 10-hour overnight fast. In the PREDO study plasma and in the RADIEL study serum was separated immediately and stored at -80°C until analysis, in which 225 metabolic markers were quantified by using a high-throughput proton NMR metabolomics platform (Nightingale Health Ltd, Helsinki, Finland). These metabolic measures cover multiple metabolic pathways, including 186 lipoprotein lipids and their subclasses, nine FA and seven ratios of FA, five other lipids, eight AA, three ketone bodies, and two metabolites related to fluid balance and three to gluconeogenesis and one to inflammation. Following the lead of earlier studies using this metabolomics platform, we used 68 of these metabolic measures as our primary outcomes <sup>9, 14</sup>. However, we show the results also for

Downloaded from https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab475/6311296 by Royal Library Aarhus University user on 05 July 2022

the entire metabolomics platform. Details of the experimentation and applications of the NMR metabolomics platform have been described previously  $^{15}$ . In brief, the thawed samples (260  $\mu$ L) were carefully mixed with sodium phosphate buffer (260 µL) and moved to NMR tubes. The setup is a combination of Bruker AVANCE III 500 MHz (a selective inverse room temperature probe head) and Bruker AVANCE III HD 600 MHz spectrometers (a cryogenically cooled triple resonance probe head, CryoProbe Prodigy TCI), both with the SampleJet robotic sample changer. The lipid extraction procedure was done manually (Integra Biosciences VIAFLO 96 channel electronic pipette) based on multiple extraction steps containing saturated sodium chloride solution, methanol, dichloromethane, and deuterochloroform and data were collected in full automation with the 600 MHz instrument. Computers that controlled the spectrometers do the Fourier transformations to NMR spectra and automated phasing. A centralized server performs various automated spectral processing steps, including overall signal check for missing/extra peaks, background control, baseline removal and spectral area-specific signal alignments and the spectral information was compared to 2 quality control samples. This NMR platform has been used in studies of pregnant and non-pregnant populations <sup>9, 14, 16</sup>. Of all the metabolites 37 have been validated against the standard clinical chemistry methods.

Prepregnancy overweight/obesity, gestational diabetes and hypertensive disorders

Prepregnancy BMI was calculated from prepregnancy weight and height recorded in antenatal clinic records and the Medical Birth Register and, when available, from prepregnancy weight and height measurements (the participants recruited before pregnancy) in the RADIEL study. In both cohorts, diagnoses of GDM and hypertensive disorders were extracted from medical records and verified by a jury comprising of a research nurse and two or more medical doctors.

Normal weight (BMI 18.5-24.99 kg/m<sup>2</sup>), overweight (BMI 25-30 kg/m<sup>2</sup>), and obesity (BMI  $\geq$ 30 kg/m<sup>2</sup>) were defined according to WHO guidelines <sup>17</sup>. The diagnostic thresholds for GDM were, according to the Finnish guidelines, 5.3, 10.0, and 8.6 mmol/l in a 2-hour 75 g oral glucose tolerance test <sup>18</sup>. Hypertensive disorders were assessed according to the criteria of the American College of Obstetricians and Gynecologists recommendations <sup>19</sup>. Definition for chronic hypertension (HT) was systolic/diastolic blood pressure  $\geq$ 140/90 mmHg present prepregnancy or diagnosed before 20 weeks of gestation or medication for hypertension before 20 weeks of gestation. Definition for gestation in a previously normotensive woman, and definition for PE was systolic/diastolic blood pressure  $\geq$ 140/90 mmHg with proteinuria  $\geq$ 300 mg/24 h or equivalent with dipstick in two consecutive measurements.

#### **Covariates**

We chose the covariates included in the models based on previous literature. In all models we first adjusted for maternal age <sup>9</sup>, cohort, and gestational week at the time of blood sampling (model 1). Next, we adjusted for level of maternal education (basic/secondary vs. tertiary) <sup>9</sup>, parity <sup>9, 14</sup>, and substance (tobacco and alcohol no vs. yes) use during pregnancy <sup>14</sup> (model 2). In additional models (model 3), overweight and obesity were further adjusted for GDM and hypertensive disorders, and analyses of GDM and hypertensive disorders were additionally adjusted for BMI <sup>9</sup>, and GDM further for hypertensive disorders, and hypertensive disorders for GDM. We also assessed the potential confounding of the intervention trials in the PREDO and RADIEL studies. Supplemental figures 1 and 2 show that interventions were not associated with the metabolic markers during pregnancy, thus, intervention was not accounted for in the analyses. The effect of different samples, serum and plasma, was accounted by the adjustment for cohort.

#### Statistical analysis

To study associations of maternal overweight/obesity, GDM and hypertensive disorders with the levels of and with change in the levels of metabolic measures during pregnancy, we applied individual-participant data meta-analytic approach by using mixed model regression analyses. In these analyses, the repeated metabolic measures represented the within-person outcome variables, and gestational week at the blood sampling the time-varying within-person predictor variable. Normal weight vs overweight / obesity, normoglycemia vs GDM, normoglycemia vs insulin / diet treated GDM, and normotension vs HT / gestational hypertension / PE were included into these models as between-person fixed effects to test if the levels of maternal metabolic measures differed according to these pregnancy conditions. Interaction between normal weight vs overweight/obesity, normoglycemia vs GDM, and normotension vs HT/gestational hypertension/PE x gestational week at blood sampling tested if the within-person change in the levels of the metabolic measures during pregnancy differed between these pregnancy conditions. We defined unstructured covariance and first-order autoregressive error covariance matrices, used the cohort as a fixed effect, and allowed random effects to account for individual differences in the intercept and in the time-varying gestational week-related slopes.

To identify women with different metabolic profiles during pregnancy we applied latent class analysis (LCA). For these analyses we pooled data for each metabolic measure from the three sampling points into a grand average. We compared solutions with two to six latent classes. Based on criteria for the optimal number of classes described by Kongsted and Nielsen <sup>20</sup>, the optimal solution was based on (1) goodness-of-fit criteria (Akaike Information Criterion [AIC], Bayesian Information Criterion [BIC]), (2) reasonable distribution of participants across subgroups (at least 10% of the sample), (3) high certainty of classification identified by posterior probabilities, and (4) clear clinical characteristics of the participants within each of the identified groups. We applied logistic regression analysis to examine if the odds to belong to latent classes, identified by the LCA as the optimal, varied according to the pregnancy conditions.

The associations were adjusted for all covariates. Data were missing for substance use and education level (Table 1) and missing values in these variables were coded into a separate category.

The metabolic measures were log-transformed to normalize their distributions. We analyzed the values in standardized units with the SDs summarized in the combined sample so that they had the same value in both cohorts. Due to significant amount of collinearity in the metabolomics data, standard Bonferroni-correction for multiple testing may be overly conservative and increase the risk of type II error <sup>21</sup>. To overcome this risk, we applied principal components analysis (PCA) approach, which is one of the most commonly used methods to reduce multidimensionality in metabolomics data and determine the number of independent tests <sup>14, 16, 22-24</sup> and is suggested as the first step in approaching metabolomics data analysis <sup>21</sup>. This approach is analogous to multiple comparison correction routinely applied in genome-wide association studies, where the significance level is set up based on the assumption of the number of independent loci in the genome <sup>25-28</sup>. Hence, by using the PCA approach, we identified twenty-five principal components, which explained over 99% of the variation in the 68 metabolic measures that we used as the primary outcomes. Therefore, two-sided P<0.002 (0.05/25) was used to infer statistical significance.

As effect size indicators we present estimates and their 99.8% confidence intervals (CI) (mixed model) and odds ratios and their 95% CIs (OR, logistic regression models). Estimates represent mean differences (pooling data from the three sampling points into a grand average) and differences in the change (estimate of slope) of the metabolic measures across the three sampling points between women with and without the pregnancy condition. If the estimate reflecting differences in the level of change is negative, the metabolic measure increases less or decreases more, and if the estimate is positive, the metabolic measure increases more or decreases less during pregnancy in women with the disorder compared to women without the disorder.

Statistical analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC). The circular diagrams were created using R (R Core Team 2020) EpiViz package <sup>29-31</sup>.

#### Results

Women in the PREDO study were younger, had higher education, were less often obese and had more often chronic or gestational hypertension or PE than women in the RADIEL study (Table 1). The second and third sampling points in the PREDO study were at an earlier gestational stage than in the RADIEL study. Of the study population, 524 (70.7%) women provided all three blood samples, 169 (22.8%) two samples, and 48 (6.5%) one sample (Table 1) and the number of samples at first time point was 625, at second 666 and at third 667.

The results for all the 225 metabolic measures are presented as circular diagrams in the supplementary material (Supplemental figures 3, 4 and 5)  $^{32}$  and results of the 68 metabolic measures used as the primary outcomes are presented in Figures 2-5.

#### Prepregnancy overweight and obesity

Compared to normal-weight women, women with obesity had higher mean levels (pooled across the three measurement points) of many lipoprotein lipids including all very-low-density lipoprotein (VLDL) subclasses and mean diameter of VLDL particles, small high-density (HDL) particles, cholesterol and triglycerides in VLDL and total triglycerides; monounsaturated fatty acids (MUFA), saturated fatty acids (SFA), and MUFA to total FA ratio; branched-chain amino acids (BCAA) and aromatic amino acids (AAA); and inflammation marker glycoprotein acetyls (GlycA) in the fully adjusted model, including adjustment for GDM and hypertensive disorders (Figure 2, left panel). Women with obesity had lower mean levels of very large and large HDL lipoprotein subclasses and mean diameter for HDL particles, and some FA ratios, including polyunsaturated fatty acids (PUFA) to total FA ratio. Out of the 68 metabolic measures, the change in the levels of 43 measures across the three sampling points was significantly different (smaller increase in 41 measures, greater decrease in valine and smaller decrease in albumin) between obese and normal weight women in the fully adjusted model (Figure 2, right panel; Supplemental figure 6). The results were similar when comparing overweight women with normal-weight women, although the levels of metabolic measures and their change were less pronounced and not always statistically significant.

#### Gestational diabetes

Compared to normoglycemic women, women with GDM had higher / lower mean levels of many of the same metabolites as obesity (Figure 3, left panel). Of the 68 metabolic measures, 23 associations were significant in the model 1, but when fully adjusted, including adjustment for BMI and hypertensive disorders, nine of the associations were rendered non-significant (Figure 3, left panel). The associations that remained significant after full adjustment included all VLDL subclasses (except for very small size), mean diameter for VLDL, VLDL and total triglycerides; BCAA isoleucine and leucine; linoleic to total FA ratio; and the inflammation marker, GlycA. Out of the 68 metabolic measures, the change in the levels of six measures across the three sampling points differed between GDM and normoglycemic women in the fully adjusted model (Figure 3, right panel; Supplemental figure 7). The differences between normoglycemic and GDM women were more pronounced in insulin-treated than in diet-treated group (Supplemental figure 8).

#### Hypertensive pregnancy disorders

PE was associated with higher / lower mean levels of many of the same metabolites as obesity. Of the 68 metabolic measures, 19 association were significant in model 1, but when fully adjusted, including adjustment for BMI and GDM, nine were rendered non-significant (Figure 4, left panel). The associations that remained significant after full adjustment were five lipoprotein subclasses

(from extremely large to small VLDL), total triglycerides and triglycerides in VLDL, MUFA, isoleucine and leucine. Out of the 68 metabolic measures, the change in the levels of two measures across the three sampling points differed between women with PE and normotension in the fully adjusted model (Figure 4, right panel; Supplemental figure 9).

HT was also associated with higher / lower mean levels of many of the same metabolites as obesity, but many of them were rendered non-significant after adjustment for BMI and GDM. Out of the 68 metabolic measures, 24 of the 29 significant associations (in model 1) became non-significant (Figure 5, left panel). The associations that remained significant were total triglycerides, MUFA, citrate, isoleucine and GlycA. Out of the 68 metabolic measures, change in the levels of three measures across the three sampling points differed between women with HT and normotension in models adjusted for all covariates (Figure 5, right panel; Supplemental figure 9).

Gestational hypertension was not associated significantly with any of the metabolic measures during pregnancy (Supplemental figure 10).

#### Metabolic profiles: Latent class analysis

The optimal LCA solution identified three classes of women who differed significantly for 52 out of 68 metabolic measures, and additionally 9 metabolic measures differed significantly between two classes (Supplemental tables 1 and 2). Supplemental table 3 shows the number of women in the three latent classes according to different pregnancy conditions. Metabolic profile of women in the class 3 was characterized by higher levels of lipoproteins, cholesterol, triglycerides, AA, GlycA and lower ratio of PUFA to total FA. With the exception of acetate and some fatty acid ratios, the levels of most metabolites gradually increased from classes 1 to classes 2 and 3 (Supplemental table 2). Across all adjustment models women with obesity compared to women with normal weight had significantly higher odds to belong to class 3 than 1 and women with PE compared with those with normotension had a significantly higher odds to belong to class 2 than 1 (Table 2).

#### Discussion

Our study shows that women with prepregnancy obesity have adverse levels of metabolic measures throughout three time points during pregnancy and smaller pregnancy-induced changes in the levels compared to normal weight women. Women with obesity displayed higher lipoprotein levels during pregnancy, their fatty acid levels were characterized by higher MUFA and SFA and lower relative levels of PUFA to total FA, their amino acid levels were characterized by higher BCAA and AAA, and they displayed higher level of GlycA when compared to normal weight women. The metabolic profile of women with prepregnancy obesity was characterized by a pattern that recapitulated the bivariate associations and pointed to profound and broad metabolic perturbations. Metabolic alterations related with GDM, PE and HT resembled the alterations related with obesity.

Our study clearly highlights the broad attenuated metabolic response to pregnancy among women with obesity. Most metabolic markers demonstrated smaller changes across pregnancy in obese than in normal weight women. Metabolic response to pregnancy, evaluated by insulin resistance, converges by the end of pregnancy between women with severe obesity and normal-weight according to a study by Forbes et al <sup>33</sup>. We have now shown the same kind of convergence in a broader set of metabolic markers. In another study the ability of pregnant women with obesity to adapt to changes in energy fuel demands (e.g. from fasting to a postabsorptive state) was less flexible and they displayed higher inflammation marker levels after test meal <sup>34</sup>. Obesity, metabolic inflexibility and inflammation may enhance each other resulting in adverse long-term effects, such as increased triglycerides, impaired glucose metabolism and insulin resistance <sup>35</sup>. Interestingly, in our study, adaptability to pregnancy in women with GDM, PE, or HT seemed, in turn, to be quite similar to women without these complications.

We showed that prepregnancy obesity was associated with atherogenic alterations in lipoproteins consisting of higher levels and larger VLDL particles, smaller HDL particles, and higher levels of triglycerides as well as with high levels of MUFA and SFA and low relative levels of PUFA across pregnancy. Similar adverse lipoprotein levels have been previously presented in cross-sectional studies<sup>9,36</sup>. Women with obesity demonstrate net lipolysis, e.g. release of free FA mainly from adipose tissue, throughout pregnancy, in contrast with normal weight women who demonstrate anabolic lipogenesis in early gestation and lipolysis in late gestation <sup>11</sup>. Accordingly, the levels of FA in women with obesity in our study were unfavorable already in early pregnancy and stayed at a perturbed level across pregnancy. Obesity-enhanced lipolysis, insulin resistance and increased inflammation induce hypertriglyceridemia and VLDL secretion from liver <sup>37</sup>. Also, reduced activity of lipoprotein lipase, results in higher levels of circulating VLDL lipoproteins and triglycerides <sup>37</sup>. Excess VLDL may provoke endothelial and placental dysfunction, which have been suggested to explain the associations between maternal hyperlipidemia, obesity, PE and GDM <sup>38</sup>. The high MUFA levels in obesity and pregnancy disorders are probably a consequence of increased lipolysis, lack of fatty acid oxidation and increased de novo lipogenesis<sup>39</sup>. In our study, obesity was associated with a lower ratio of PUFA to total FA that is mainly a consequence of higher total levels of MUFA and SFA. The impact of low relative levels of PUFA on the fetal development should be studied further.

Our longitudinal study strengthens the findings of cross-sectional studies showing prepregnancy obesity to be associated with high levels of BCAA and AAA<sup>9, 36</sup>. Reduced utilization of BCAAs in liver and adipose tissue, and de novo synthesis of BCAAs by gut microbiota contribute to accumulation of BCAAs in plasma, and obesity is tightly related to reduced activity of BCAA catabolism enzymes and to the changes in the microbiota<sup>40</sup>. BCAAs have also been causally linked with insulin resistance<sup>40</sup>. In contrast to leucine and isoleucine, we found valine levels decreasing during pregnancy, as seen before<sup>14</sup>. Additionally, we demonstrated a greater decrease in obese compared to normal-weight women. It has been hypothesized that valine might have different metabolic effects depending on the adiposity status<sup>40</sup>.

Underlying pathophysiologic processes, insulin resistance, low-grade inflammation, oxidative stress and endothelial dysfunction <sup>41</sup>, along with coexistence of obesity and pregnancy disorders, may explain the similarities in metabolic profiles of obesity, GDM, PE and HT. The origins of GDM, PE and

HT are, however, complex and multifactorial, related to genetic predisposition or lifestyle factors <sup>42</sup>. In our study, metabolic measures which remained significantly associated with GDM and PE in fully adjusted models, were many VLDL measures, triglycerides, some FA and BCAAs isoleucine and leucine, as seen also in the previous cross-sectional studies <sup>9, 43-45</sup>. In non-pregnant populations HT has also been associated with increased concentrations of many lipids like VLDL and triglycerides <sup>46</sup> which was also seen in our study but rendered non-significant after adjustment for BMI and GDM.

We demonstrated persistently higher levels of inflammation marker GlycA across pregnancy complicated by obesity, GDM and HT. GlycA is a marker of inflammation associated with multiple metabolic aberrations including type 2 diabetes and cardiovascular disease <sup>47</sup>. GlycA levels elevate during normal pregnancy <sup>14</sup> and are higher in obese than in overweight pregnant women <sup>36</sup>. In our study PE was not independently associated with GlycA levels, but inflammation of PE could have been demonstrated by using a broader panel of inflammation markers.

The strength of our study lies in its longitudinal study design, which allowed us not only to study mean levels of the metabolic markers but change in their levels across three serial time points during pregnancy. The targeted panel of metabolic measures we used has been widely studied previously in pregnant and non-pregnant populations and some of the metabolites have been proved to give quantitative results comparable to conventional laboratory techniques <sup>15</sup>. Furthermore, our sample included women at risk for GDM and PE. This resulted in higher number of women with overweight/obesity, GDM and hypertensive disorders in our sample than seen in a general population of pregnant women, which provided higher statistical power to detect associations. Despite the large sample size, in latent class analyses using categorical rather than continuous outcome, the power was still limited as our predictor variables were dichotomous. The targeted metabolomics panel precludes discovery of novel molecules and high-risk sample limits generalizations to all pregnant women. Generalizability may also be limited by the fact that both study populations came from a Nordic high-income country. The studies collected different samples, plasma and serum, but to our knowledge, the plausible bias due to different samples is minimal <sup>48</sup> and we have addressed the issue by applying the statistical methods with SD scaling and adjustment for cohort. Combining two cohorts generates a challenge of wide time range in blood sampling points which might diminish some of the findings.

In conclusion, our findings indicate that, when compared to normal-weight, women with prepregnancy obesity have profoundly perturbed metabolic levels and profiles during pregnancy and display smaller pregnancy-induced change in the levels of the metabolic measures. The metabolic perturbations in pregnancies complicated by GDM, PE and HT resembled the perturbations seen in obesity but some of these associations were explained by BMI. Future studies are warranted to explore the influence of disturbed maternal metabolome on long-term maternal health as well as newborn metabolic health and growth.

#### Acknowledgments

The authors' responsibilities were as follows— KR, HML, EK, PMV, EH, SBK, JGE, EH and BASL: designed the research; KR, HML, EK, PMV, EH, SBK, JGE, EH and BASL conducted research; PVG, JK and HSH: analyzed the data and performed statistical analysis; JK, HSH, PVG, KR and SBK: wrote the manuscript; JK, HSH, KR and SBK: had primary responsibility for final content; and all read and approved the final manuscript. The authors report no conflicts of interest.

#### **Data Availability**

çcei

Datasets generated during the current study are not publicly available but will be made available upon reasonable request. Requests are subject to further review by the national register authority and by the ethical committees.

1. World Health Organization. Obesity and overweight. Available at:

https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed Jul 7, 2020.

2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet.* The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved; 2017;390:2627-2642.

3. Santos S, Voerman E, Amiano P, et al. Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data metaanalysis of European, North American and Australian cohorts. *BJOG*. 2019;126:984-995.

4. Godfrey KM, Reynolds RM, Prescott SL, et al. Influence of maternal obesity on the long-term health of offspring. *Lancet Diabetes Endocrinol*. 2017;5:53-64.

5. Hellmuth C, Lindsay KL, Uhl O, et al. Maternal Metabolomic Profile and Fetal Programming of Offspring Adiposity: Identification of Potentially Protective Lipid Metabolites. *Mol Nutr Food Res.* 2019;63:e1700889.

 Kadakia R, Nodzenski M, Talbot O, et al. Maternal metabolites during pregnancy are associated with newborn outcomes and hyperinsulinaemia across ancestries. *Diabetologia*. 2019;62:473-484.

7. Mills HL, Patel N, White SL, et al. The effect of a lifestyle intervention in obese pregnant women on gestational metabolic profiles: findings from the UK Pregnancies Better Eating and Activity Trial (UPBEAT) randomised controlled trial. *BMC Med.* 2019;17:15-7.

 Jacob S, Nodzenski M, Reisetter AC, et al. Targeted Metabolomics Demonstrates Distinct and Overlapping Maternal Metabolites Associated With BMI, Glucose, and Insulin Sensitivity During Pregnancy Across Four Ancestry Groups. *Diabetes Care*. 2017;40:911-919.

 9. Taylor K, Ferreira DLS, West J, Yang T, Caputo M, Lawlor DA. Differences in Pregnancy Metabolic Profiles and Their Determinants between White European and South Asian Women: Findings from the Born in Bradford Cohort. *Metabolites*. 2019;9:190. doi: 10.3390/metabo9090190.

10. Kelly RS, Croteau-Chonka DC, Dahlin A, et al. Integration of metabolomic and transcriptomic networks in pregnant women reveals biological pathways and predictive signatures associated with preeclampsia. *Metabolomics*. 2017;13:7. doi: 10.1007/s11306-8.
Epub 2016 Dec 12.

11. Lain KY, Catalano PM. Metabolic changes in pregnancy. *Clin Obstet Gynecol*.2007;50:938-948.

12. Girchenko P, Lahti M, Tuovinen S, et al. Cohort Profile: Prediction and prevention of preeclampsia and intrauterine growth restriction (PREDO) study. *Int J Epidemiol*.
2017;46:1380-1381g.

13. Rönö K, Stach-Lempinen B, Klemetti MM, et al. Prevention of gestational diabetes through lifestyle intervention: study design and methods of a Finnish randomized controlled multicenter trial (RADIEL). *BMC Pregnancy Childbirth*. 2014;14:70-70.

14. Wang Q, Würtz P, Auro K, et al. Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence. *BMC Med.* 2016;14:205-0.

15. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ Cardiovasc Genet*. 2015;8:192-206.

16. Würtz P, Cook S, Wang Q, et al. Metabolic profiling of alcohol consumption in 9778 young adults. *Int J Epidemiol*. 2016;45:1493-1506.

17. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organization technical report series*. 2000;894:i.

18. Kaaja R, Kivelä R, Kukkonen-Harjula K, et al. Raskausdiabetes : Käypä hoito -suositus. *Duodecim.* 2008;124:1556-1569.

American College of Obstetricians and Gynecologists. Hypertension in pregnancy.
 Report of the American College of Obstetricians and Gynecologists' Task Force on
 Hypertension in Pregnancy. *Obstetrics and Gynecology*. 2013;122:1122-1131.

20. Kongsted A, Nielsen AM. Latent Class Analysis in health research. *J Physiother*. 2017;63:55-58.

21. Alonso A, Marsal S, Julià A. Analytical methods in untargeted metabolomics: state of the art in 2015. *Front Bioeng Biotechnol*. 2015;3:23.

22. Sliz E, Kettunen J, Holmes MV, et al. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. *Circulation*. 2018;138:2499-2512.

23. Bell JA, Carslake D, Wade KH, et al. Influence of puberty timing on adiposity and cardiometabolic traits: A Mendelian randomisation study. *PLoS Med.* 2018;15:e1002641.

24. Beynon RA, Richmond RC, Santos Ferreira DL, et al. Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial. *Int J Cancer*. 2019;144:1918-1928.

25. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. *Genet Epidemiol*.
2008;32:361-369.

26. Galwey NW. A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests. *Genet Epidemiol.* 2009;33:559-568.

27. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. *Heredity (Edinb)*. 2005;95:221-227.

28. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet*. 2004;74:765-769.

29. Lee MA, Mahmoud P, Hughes D, et al. Epiviz: an implementation of Circos plots for epidemiologists. . <u>https://github.com/mattlee821/EpiViz</u>:2020.

30. Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize Implements and enhances circular visualization in R. *Bioinformatics (Oxford, England)*. 2014;30:2811-2812.

31. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics (Oxford, England)*. 2016;32:2847-2849.

32. Kivelä J, Sormunen-Harju H. Longitudinal metabolic profiling of maternal obesity, gestational diabetes and hypertensive pregnancy disorders - Supplemental material.

33. Forbes S, Barr SM, Reynolds RM, et al. Convergence in insulin resistance between very severely obese and lean women at the end of pregnancy. *Diabetologia*. 2015;58:2615-2626.

34. Tinius RA, Blankenship MM, Furgal KE, et al. Metabolic flexibility is impaired in women who are pregnant and overweight/obese and related to insulin resistance and inflammation. *Metabolism*. 2020;104:154142.

35. Goodpaster BH, Sparks LM. Metabolic Flexibility in Health and Disease. *Cell Metab*.2017;25:1027-1036.

36. Houttu N, Mokkala K, Laitinen K. Overweight and obesity status in pregnant women are related to intestinal microbiota and serum metabolic and inflammatory profiles. *Clin Nutr*. 2018;37:1955-1966.

37. Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. *J Clin Lipidol*. 2013;7:304-383.

38. Contreras-Duarte S, Carvajal L, Garchitorena MJ, et al. Gestational Diabetes Mellitus Treatment Schemes Modify Maternal Plasma Cholesterol Levels Dependent to Women's Weight: Possible Impact on Feto-Placental Vascular Function. *Nutrients*. 2020;12:506.

39. Frigolet ME, Gutiérrez-Aguilar R. The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease. *Adv Nutr*. 2017;8:173S-181S.

40. Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? *Cell Metab*. 2017;25:43-56.

41. McElwain CJ, Tuboly E, McCarthy FP, McCarthy CM. Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health? *Front Endocrinol.* 2020;11.

42. Weissgerber TL, Mudd LM. Preeclampsia and Diabetes. Curr Diab Rep. 2015;15:579.

43. Mokkala K, Vahlberg T, Pellonperä O, Houttu N, Koivuniemi E, Laitinen K. Distinct Metabolic Profile in Early Pregnancy of Overweight and Obese Women Developing Gestational Diabetes. *J Nutr.* 2020;150:31-37.

44. Villa PM, Laivuori H, Kajantie E, Kaaja R. Free fatty acid profiles in preeclampsia. *Prostaglandins Leukot Essent Fatty Acids*. 2009;81:17-21.

45. White SL, Lawlor DA, Briley AL, et al. Early Antenatal Prediction of Gestational Diabetes in Obese Women: Development of Prediction Tools for Targeted Intervention. *PLoS One*. 2016;11:e0167846.

46. Onuh JO, Aliani M. Metabolomics profiling in hypertension and blood pressure regulation: a review. *Clin Hypertens*. 2020;26:23-9.

47. Ritchie SC, Würtz P, Nath AP, et al. The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection. *Cell Syst.* 2015;1:293-301.

48. Jiménez B, Holmes E, Heude C, et al. Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by 1H NMR Spectroscopy in a Multilaboratory Trial. *Anal Chem.* 2018;90:11962-11971. Figure 1 Flowchart of the participants.

**Figure 2** Mean differences (pooled mean across the three consecutive measurement points; left panel) and differences in the change (slopes; right panel) of metabolic measures during pregnancy between women with prepregnancy overweight or obesity in comparison to women with normal weight. Dots refer to mean differences and change per one pregnancy week in the metabolic measures in SD units and error bars to their 99.8% confidence intervals between overweight (gray) and normal weight women and between obese (black) and normal weight women. In the analyses of mean differences (main effect models) the associations were adjusted for gestational week at the time of blood sampling, cohort and maternal age and the analyses of change (interaction models) additionally for the main effects of prepregnancy overweight/obesity (model 1; dots and bars); further adjustments included parity, education and substance use during pregnancy (significance is indicated with OW2 for overweight and OB2 for women with obesity), and gestational diabetes and hypertensive disorders (significance is indicated with OW3 for overweight and OB3 for women with obesity).

**Figure 3** Mean differences (pooled mean across the three consecutive measurement points; left panel) and differences in the change (slopes; right panel) of metabolic measures during pregnancy between women with gestational diabetes in comparison to normoglycemic women. Dots refer to mean differences and change per one pregnancy week in the metabolic measures in SD units and error bars to their 99.8% confidence intervals. In the analyses of mean differences (main effect models) the associations were adjusted for gestational week at the time of blood sampling, cohort and maternal age and the analyses of change (interaction models) additionally for the main effects of gestational diabetes (model 1; dots and bars); further adjustments included parity, education and substance use during pregnancy (significance is indicated with GDM2), and body mass index and hypertensive disorders (significance is indicated with GDM3).

**Figure 4** Mean differences (pooled mean across the three consecutive measurement points; left panel) and differences in the change (slopes; right panel) of metabolic measures during pregnancy between women with preeclampsia in comparison to normotensive women. Dots refer to mean differences and change per one pregnancy week in the metabolic measures in SD units and error bars to their 99.8% confidence intervals. In the analyses of mean differences (main effect models) the associations were adjusted for gestational week at the time of blood sampling, cohort and maternal age and the analyses of change (interaction models) additionally for the main effects of preeclampsia (model 1; dots and bars); further adjustments included parity, education and substance use during pregnancy (significance is indicated with PE2), and body mass index and gestational diabetes (significance is indicated with PE3).

**Figure 5** Mean differences (pooled mean across the three consecutive measurement points; left panel) and differences in the change (slopes; right panel) of metabolic measures during pregnancy between women with chronic hypertension in comparison to normotensive women. Dots refer to mean differences and change per one pregnancy week in the metabolic measures in SD units and error bars to their 99.8% confidence intervals. In the analyses of mean differences (main effect models) the associations were adjusted for gestational week at the time of blood sampling, cohort and maternal age and the analyses of change (interaction models) additionally for the main effects of chronic hypertension (model 1; dots and bars); further adjustments included parity, education and substance use during pregnancy (significance is indicated with HT2), and body mass index and gestational diabetes (significance is indicated with HT3).


		2()
	Mean (SD) or N (S	
	PREDO	RADIEL
	(N=404)	(N=337)
Gestational age at the 1 <sup>st</sup> blood sampling point (mean, range)	13.0 (11.1-16.7)	13.0 (6.0-17.7)
Gestational age at the 2 <sup>nd</sup> blood sapling point (mean, range)	19.4 (17.1-22.9)	23.1 (20.1-27.6)
Gestational age at the 3 <sup>rd</sup> blood sampling point (mean, range)	27.0 (24.1-31.1)	35.1 (30.6-38.9)
Maternal age, years	32.6 (5.2)	33.4 (4.5)
Data not available	0	0
Education level		
Secondary or lower	196 (49.5%)	232 (69.0%)
Tertiary	200 (51.5%)	104 (31.0%)
Data not available	8 (1.1%)	1 (0.3%)
Parity		
Primiparous	128 (31.7%)	114 (33.8%)
Multiparous	276 (68.3%)	223 (66.2%)
Data not available	0	0
Smoking during pregnancy		
No	374 (93.3%)	323 (96.1%)
Smoked at any time during pregnancy	27 (6.7%)	13 (3.9%)
Data not available	3 (0.7%)	1 (0.3%)
Alcohol use during pregnancy		
No	308 (86.5%)	315 (95.2%)
Yes	48 (13.5%)	16 (4.8%)
Data not available	48 (11.9%)	6 (1.8%)
Body mass index category		
Normal weight (18.5-24.99 kg/m <sup>2</sup> )	195 (48.3%)	69 (20.7%)
Overweight (25-29.99 kg/m <sup>2</sup> )	85 (21.0%)	45 (13.4%)
Obese (≥30 kg/m <sup>2</sup> )	124 (30.7%)	223 (66.2%)
Data not available	0	0
Hypertensive disorders		
Normotension	254 (62.9%)	292 (86.7%)
Gestational hypertension	36 (8.9%)	16 (4.8%)
Preeclampsia	43 (10.6%)	11 (3.3%)
Chronic hypertension	71 (17.6%)	18 (5.4%)
Data not available	0	0
Gestational diabetes mellitus		
Normoglycemia	314 (77.7%)	243 (71.22%)
Gestational diabetes mellitus	90 (22.3%)	94 (27.9%)
Data not available	0	0
Data not available	0	0

**Table 2.** Odds ratio (OR) with 95% confidence intervals (CI) for women with overweight, obesity, gestational diabetes and hypertensive disorders to belong to latent classes with different metabolic profiles during pregnancy

	Latent	class 2 versus	latent	Laten	Latent class 3 versus latent class							
	class 1			1								
	OR	95% CI	Р	OR	95% CI	Р						
Overweight versus normal weight												
Model 1	1.32	0.77, 2.26	0.31	1.75	0.90, 3.43	0.10						
Model 2	1.46	0.83, 2.56	0.19	1.90	0.96, 3.78	0.07						
Model 3	1.29	0.73, 2.30	0.38	1.74	0.87, 3.51	0.12						
Obesity versus normal weight												
Model 1	1.74	1.10, 3.43	0.02	2.02	1.16, 3.35	0.01						
Model 2	1.64	1.01, 2.64	0.04	2.12	1.19, 3.80	0.01						
Model 3	1.46	0.89, 2.40	0.13	1.95 <	1.08, 3.52	0.03						
Gestational diabetes versus no diabetes					$\sim$							
Model 1	1.51	0.92, 2.47	0.11	1.39	0.78, 2.47	0.26						
Model 2	1.53	0.92, 2.55	0.10	1.34	0.75, 2.41	0.33						
Model 3	1.41	0.84, 2.36	0.19	1.23	0.68, 2.22	0.49						
Gestational hypertension versus normotensio	n											
Model 1	1.11	0.53, 2.29	0.79	1.20	0.48, 3.00	0.69						
Model 2	1.07	0.51, 2.26	0.86	1.18	0.47, 2.98	0.72						
Model 3	1.03	0.49, 2.19	0.94	1.10	0.43, 2.79	0.84						
Preeclampsia versus normotension												
Model 1	2.34	1.04, 5.27	0.04	2.32	0.85, 6.32	0.10						
Model 2	2.80	1.17, 6.72	0.02	2.73	0.95, 7.82	0.06						
Model 3	2.58	1.06, 6.23	0.04	2.36	0.81, 6.84	0.11						
Chronic hypertension versus normotension												
Model 1	2.63	1.31, 5.29	0.007	3.06	1.33, 7.01	0.008						
Model 2	2.25	1.11, 4,59	0.03	2.81	1.21, 6.49	0.02						
Model 3	2.04	0.99, 4.21	0.054	2.37	1.01, 5.58	0.05						

Model 1 is adjusted for maternal age and cohort, model 2 additionally for maternal education, parity and substance use during pregnancy and model 3 additionally for gestational diabetes and hypertensive disorders (in analyses of overweight and obesity), or for body mass index and hypertensive disorders (in analyses of gestational diabetes), or for body mass index and gestational diabetes (in analyses of hypertensive disorders)

Figure 1



\*Risk factors for PE and IUGR: prepregnancy BMI≥30kg/m2, previous pregnancy complication like PE, intrauterine growth restriction, GDM or fetal demise; prepregnancy obesity; chronic hypertension; type 1 diabetes; age below 20 or above 40 years; systemic lupus erythematosus; or Sjögren's syndrome.

PE preecla mpsia; GDM gestational dia betes; IUGR intrauterine growth restriction



	Mean	difference betv	veen groups					Difference in the ch	ange between g	oups				
	1 1 1	1.1.1	1 1 1 1	11			1.2	1 1 1 1	1 2 2 3					
Lipoprotein subclasses	2.11	2	4 4° 4 14				18	* * *) *						
Extramply large VLEL	1994 199	5 8 15		C/62	CB2	G493 C	81					CB2		OB3
Very large VLDL	10.0	4 32 10	·	- OW2	082	OW3 O	83 -	-		a na ta		OB2		OB3
Large VLOL	1.11 1.1	4 4 4		. 0.02	9.0	one o	10	· · · · · · ·	1 i i i	a 34 à		002		COD
Medium VLDL	5.0 0.2	2 25 18		OW2	OB2	OW3 0	83	1 1 1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	1 50			OB2		OBS
SmallVLD.		1 1 2		CV2	CR2	CW3 C	80		1			CB3		085
Very small VLDL	<ul> <li>(1) \$ (1)</li> </ul>	+ + <del>-</del>		- OW2	OB2	OW3 0	83 -		8.83	- 20 9	0.W2	OB2	OW3	OB3
ri,	· · · · · ·	+ 1	<u></u>	**					+		(1/2	OB2	ans	CB3
Large LDL	1.1.1			33			1.8	·	12.1		OW2	082	OW3	OB3
Neduri JDL				1			1		16		0.12	CUZ	CAV3	CUS
SmullLDL	-17 H -17		+ + +	8			- 64	-	18 KS	- 18 B	OW2	OB2	CW3	083
Very large HDI	100 te		t t t t	C/62	090	00/3 0	P3		-	1 11 1		QB2		085
Lage HOL				OW2	OB2	OW3 0	83 .	8 8 C	·					
Nedlah (DL	1.1		<u> </u>		052	C	. 00	1 1 1		1 3 3				
Small HDL	F + +			OW2	OB2	OW3 0	83	1 1 F						
Lipoprotain particle size			+ + + + +	-100805			100000000	+ +	1 H H					
Mean dia meter for VLOL particles	i i i i	a	-	OW2	OB2	OW3 0	83							
Mean demater for LDL carboney	* ***	1 1 2	+ + + +	1	0.2	0	15	+ + <u>+</u>		1 17 1		062		DB5
Mean dia meter for HDL particles	interested in the local division of the loca	_	r ( 1771)	OW2		OW3 0	83	1 1 1 month	-					
Ghalesteral	10110-10	a a   1	1.1.1.1.1.1	t :				a a 2010	10	1.1.1.1.1				
To tal choleste rol	10220-1035			10			1.4		1 N N		OW2	082	QW3	083
Lools: a advart in VLD.		_		CAN2	052	09/3 0	83				002	CB2	CIV/2	OB3
Total cholesteral in LDL				-			1				OW2	OB2	QW3	OB3
to al cho estero in HDL	100 522		1 1 1 1 1	032	0.2	- 6	15	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		1 13 1				
Total choleste rol in HDL2	12.1 12		1 1 1 1	OW2			83			1 1 1				
Total croiestore in HDL3	1000								_			C82		083
Remount choices to roll	10.14		9 (B) (C) (C)	JW2	OB2		1.4		+111		OW2	082	OV3	OB3
Ease fiel c obstand								1	100		3/2	OB2	UVR	CB3
Freechoksterol	101 10			11			14			1.12	OW2	082	OW3	OB3
Glycerkies and phospholipids			1 1 1 1 1 1 1 1 1					1 1 2 2	+10		Service.		Ser. 2	
Total biglyce idea	**** +***	1 1 1		OW2	OB2	OW3 0	83		t			082		083
Thig spanides in of 19	101 10		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0362		035 0			-	1 1 1		OB2		OBS
Triglyce idea in LDL	1.1.1.1	1 1 +•		-	OB2		1			1 1 1		082		OB3
Trigstendes ni Du	1.1 K-S		1.1.1. 1.1.1.	+1	CUE		111	1. 1		1 24 2		CO2		003
Total phosphoglycerides			· · · ·	1			- 13			1		OB2		OBS
Flosphologic and a shorthal is	10.1	· 1		1			1.4		-			CB2		OB3
Total cholines							12		1			OB2		OBS
Springerryakn	10004 1000	1	to the state	40			114	4104004004	405	4 4 4		002		005
Apolipoproteins								· · · · ·				0.02		005
Applipoproteins Applipoprotein A		_							-			C62		080
Application B		-	1 1 1 1 1	OW2	092	OW3 0	83	4 4 4 4 4 4	10		OW2	082	<b>G</b> //3	083
Reional Realization of the Barkoolization A-L	6.01 H25		+	CW2		0.43 0			+110			CB2	CIVI2	OB3
Second Participation of the second second second	-			- Alle	124	Sara G					der.	CALLS.	10.0	CALC:
	-10 -0.6	-0.2 0	12 0.6	1.0			-0.05	-003 -001	0.01 0	03 0.0	6			
		SD units (99.8							99.8%C1)					
			12.5.1.1.5.5											

Downloaded from https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab475/6311296 by Royal Library Aarhus University user on 05 July 2021

26

Fatty acids ratio Doccarecter Linoleic acid to One, a3 kJy Ornega& fatty: Polyunal, wa Mono unsutanti Salurated fails Gly colysis relate G.c.58 Rcce Loctor City H Amino acida Aanine Glutamine Halilie Branched-chair table.che Leizite Ville Aromatic amino **Frenvialanine** Typsite Keture budies Acette

	, C	Figure 2B		
	Mean difference between groups		Difference in the change between groups	
		4		ŝ
Fatty acids	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	14	a a a <u>e e</u> a a a a a	1
Docusenesero clacin Lindeki acid				C62 C63
The Contraction of Co	<del></del>	- i	· · · <b>· · · · ·</b> · · · · · ·	+
Omeça 3 fetiy es dis		21 A		OB2 OB3
Omegaē fatlyacida		1	· · · · · · · · · · · · · · · · · · ·	082 083
Prolyanisatility and faility and its	1 1 <del>1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 </del>	1		082 085
Mono unsaturated faity acids	· · · · · ·	OW2 OB2 OW3 OB3	· · · · · · · · · · · · · · · · · · ·	. 082 083
Salurated faily acids	· · · · · · · · · · ·	CS2 CB3	· · · · · · · · · · · · · · · · · · ·	C62 C63
Fatty acids ratios	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1		×
Docessessere class to icial faily acids	1		a ta ta <del>ta ta ta ta t</del> a ta ta ta	
Linoleic acid to total/arty acids		· OW2 OB2 OW3 OB3 ·	· · · · · · · · · · · · · · · · · · ·	81
Onnyo 3 kily ands kitota fally so da	+	CE2 CE3		
Ornega-6 faity acids to to tail faity acids		0W2 082 0W3 083	· · · · · · · · · · · · · · · · · · ·	-
Polyunial, weed faily acros to icial faily acros		042 052 045 055		
More unsaturated fully acids to total fully acids		· OW2 OB2 OW3 OB3 ·	· · · · · · · · · · · · · · · · · · ·	· OB2 OB3
Solurated folly acids to seal fetty acids	+ + +	÷ +	· · · · ·	
Gly colys is related metabolites		1		5 C
Gl.e.se	a sector and a sec	CB2 CB0		
Lacitie	· · · · · · · · · · · · · · · · · · ·	OB2 OB3		
Оњи	· · · · · · · · · ·	- 0%/2 CB2 - CB3 -	· · · · · · · · · · · · · · · · · · ·	
Amino acida		14		
Aanine				062 065
Glutamine		OB2 OB3		
Halidine	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	CB2 CB3	a da anti-	
Branched-chain antino acida				
table.che	and the second	. ' owe are own are '	· · · · · · · · · · · · · · · · · · ·	062 065
Lezite		- OW2 OB2 OW3 OB3	· · · · <u>· · · · · · · · · · · · · · · </u>	10.0
V-line		CS2 CB3		C62 C63
Aromatic amino acida				•
Frenvialaning	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
Tyresine		1 082 083 1	1 1	*
Keture budies				
Acette	· · · · · · · · · · · · · · · · · · ·	082 083	· · · · · · · · · · · · · · · · · · ·	
Acetoaceraie	· _ · _ · _ · _ · _ · _ · · · ·		a a a a a a a a a a a	
3-hyd roxybudy rate		· 082 083 ·	and the second	5.5
Fluid balance	- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
Creativine				
Atumi				
Inflammation			and the second	002 000
Giococien scelus		- 002 0.2 003 0.8		002 005
Cape A Are Roots		- 000 000 000 000		000
	-10 -0.6 -0.2 0.2 0.6	10 -0.0	16 -0.03 -0.01 0.01 0.03 0	105
	SD units (99.8% CI)	-0.0	SD units (99.8% Cl)	
	on sum (w.o.e.c.)		a premia faarata cit	



Mean difference between groups

Difference in the change between groups

16	Lipotrate in subclasses														
	Extends are VLD.	101-04	10.00	40 <u>100</u>	100	GEM2	CIDM3		-i-: i-:	12.14	-	+11.14			
	Verylarge VLDE.	100	10.04	400		GOM2	GDM3	12	64 - Y2	1211					
	Large VLDL		414	10	· · · · ·	15DM2	GUMD		a) a)						
	Median VLOL	1.01	1.0.1			GOM2	GDM3	24	1 1	1					
	STOLV.DL	15:35	1.51	· _	<u>, , , , , , , , , , , , , , , , , , , </u>	GEN2	SDM13	10	1.1	- 15 ( <u>†</u>	-	11.1			
	Very small VLCL						and the			-	<u></u>				
	IT.4			_						1.107					
	Large LDL	1.01	1.1	1							L				
	Netion LDL	100	100	100	10.00			1.1	3. 3	1.1.1.1	2	2003			
	SmallLCR	10.1	1.1	-					1.1		1	1-1-			
	Very large HT	1.1	1.	1				14	8.8	1.1	-	A112			
	Lage HOL	10.04	1					1.4			1				
	Nector 3L	1.11		1.0	+ +			13	H. 1	1.11		10.0			
	SmallHCE	1.1	1 1					12			10100	200			
17	Lipoprolein particle size	4.777-4	++		4			10	4 ¥	5.6		40.04			
23	Meas dame to rior VLDL carticles		1.11	1		G0M2	GOMS			1.1.1					
	Keend an eler for FOL part cas	100	dia d			Sanne -	12010.0		± ±		1				
	Mean dame to rforHDL parkies	10.00		+		GDM2		14	4.4			***			
▲ 102	Choicsterol	100	1	8 1 H		(31)/12		11				+12.04			
	Total officiests of	2010								1000	1.1.1				
	Todal charles stated in V. DL					CDM2					1				
	Total cholesae o li nL.CL		1.1			Corner			4	2804.0	1.00	A		GDM2	GDM3
	Icial choiesterol m 1.25	15.54	4	÷ .	1.15			14		10.0	1	+0.00		COURC	COURS
	Tatal choice an of the HOL2														
	Total cholestorol in FCLD										T	-			
	Remark chiesteni	1.14	+	1000				1.1	+ +	10.140		412.4			
	Ever fuel classication	12.14	1.1	1				1	÷. *		T	10.1		CDMC	CDMS
	File cholesteral	1.1.1	1.1.1					1.5	1.1					LADER	CHELS
	Styperides and phospholipids							11			TS				
	Triful tig lycerides	to cat	1	+	5 + 5	GMD	GOM3	+	+ +	1. C	1				
	Trig grandes in M.C.			1 3			CEMIS		1.1	100	T				
				1.1.1		GDAE	544010					1.1			
	Trigilyza (idea in 121).	1.1	1.1	. 15				12	1.1	SHILL		1.1			
	Tric sterides in LIDL	87 C.A	41.14	1		GEM2		÷	+ +	10.00					
	Total phosphoglyciendes	1.1	1.1	-				1	1.1		Τ.	1.1			
	Prospi sidyle ulios and other endirus	1.1	1.1	1					1. 1	1000		30 G			
	Total choines		+	-					4 4		T -				
	Colorganesia			_							2				
	Apdipoprateins	10.1	15.2	S				1.5	<ul> <li>1</li> </ul>	62.04	1.5	5.2			
	Applipaceologie A				4. 4.				+ +		-	4.5.4			
	Apolippa ta in B		1.1	1				14	14 A.		1	10.04			
	Ret o of spalip op die n Bild ap dip op die 184			1		C345			1	1	-				
		- the second	1	1				5	1		1	1			
		-10	-0.6 -0					-0.05	-0.03	8 -0.01			0.05		
			SD at	iis (99.8%)	3)					SD units	(99.8% C	9			

28

	Mean differencebetween groups		Difference in the change between groups	
atty acids			alta a pita tit	
Executed execution classic	· · · · · · · · · · · · · · · · · · ·		ala da ser en la compañía de la comp	
Linoleic acid				
Omeçia 3 ferty acids	a da		a da da <u>n an</u> da	
O meg s 6 fatty acids			1 1 1 1 <del>1 1 1</del> 1 1 1 1 1 1	
Folymeat is edifetyspices			and the second	
Mono unsaturated fatty acids		GDM2		
Saluraled laty acids				
atty acids ratios				
Docesshessend clock: to lefal faily acids	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	
Linoleic acid to total atty acids	Cat and a company according	GOM2 GDM3	and a second	
Omega-3 licity cricks in total faily of the				
Ornega-6 fatty acids to to tal fatty acids		GDM2 GDM3	and the second	
Folgunsal, recell faily across to local faily acros	and a second	GEN2 GUN3	and the second	
More unsaturated faily acids to total faily acids		GDM2 GDM3	and the second	
Solurated for y acids to swafferly acids		(10M2 (35M3		
ly colysis related metabolites			and a second	
iy colysis related metabolities		GDNE GDMS	and the second second second second	
Lactite	· · · · · · · · · · · · · · · ·	130/M2 - 30/M13	a an a an a a a a a a	
Obse		GDM2 CDM3	CDM	CDM3
		COM2 140615	CDM	E LUMB
ntino acida	* * * * * *			
Alanine				
Glutamine			and the second	
Hafain.			- 19 1월 19 <del>19 19 1</del> 2 19 19 19 19 19 19 19 19 19 19 19 19 19	
ranched-chain amino acida				
Isoleucite		GEN2 GDMD		
Leacine	· · · · · · · · · · · · · · · · · · ·	GDM2 GDM3		
Value	· · · · · · · · · · · · · · · · · · ·			
romatic amino acida				
Fromyalaring	+			
Tyrcsine				
istures buckers			a a second second	
Acette			1 1 1 1 <del>3 1 1 1 1</del> 1 1 1	
Apeloateraic				E GOME
3-hyd roxybutlyratia		GDM2	GON	E GDM3
lu d belance	and the second		and a second a second	
Ceutinine	2 2 2 2 <del>2 4 4</del> 2 2		GON	E GOM3
A bumin	4			
fammation				
Givenotemenetale	a a <u>a a</u> a	GDM2 GDM3	na an <u>na sa</u> ta a ana	

Rcce




Large VLCL Median VLDL SmallVLD\_ Very small VLOL ID. Large LDL NSON- LDL SmillDL Very large HD Lage HOL Nedlum Du S mall HDL Lipoprolain particla Melan dia meter foir 1 Maanmameter for l Me as dis motenton k Cholesterol To tal choleste tal Tatal Grandson, in To tal choleste rol in t Logi orbiestero in l Total choieste rol in l Total croipstore in l Remnant choles te ro Exertical characters Free cholesterol Giycarkies and phos To tal triglyce rides. Triggenites (NVI) Triglyce tides in LDL Trig sperides in LD\_

		Mean	difference	between g	roups				Difference in the change between groups										
	31	13/3	0.12	1 1 1	78 i	151			85	100	31.3		1 1		18	8			
Lipoprotein subclasses		+ +	4 F.		÷ +	1214				a 4		8 J I	¥ 34	- 41	+11	6			
Extremely large vil. DL		+101+ 3	10 100	-	-++	(C)+	PE2	9E3	+0	*2414				-	+00	-			
Verylarge VLDL	- 66	1. LV -	10.00			24	PE2	PE3		1.12		1	1 4	-	10	4			
Large VLOL							HL2	4.5		Sec. 1	1.2	a )							
Mediam VLDL	1		10 01		- 1 C	1.14	PE2	PE3	1.1	1.1.	11	<u> </u>	P. 1						
SmallVLD	312	esa -	10 10	1.51		130	PE2	PE3	351	13.00	30.3				111	8			
Very small VLDL							PE2								+	-			
ID				100	-														
Lage LDL	-		1. 1. H						10						110	3			
NSON- LUL		101	6 60	1.1.1.1		10.1			10	1.15	100		1.17		10	1			
Similate	1		1 1							1 1		1	1 1	1	1	2			
	14	4)m(4	1. 1.	1.1.1	- 1. A	Intia			- Xî.	1. C. 1.	16		1.18		AUS	4	220		
Sery Lage HDL Lage HDL	- 11					an te			+1-	• · · · ·					-	9	PL2		
	-		•	1	1				1.1		÷.	-		-	-	a –			
Nedur D. SmallHDL		+1									-	-	1 - 1		66410	4			
	4								40	-	-	-	-	-					
Lipoprotein particle size			1. 1.	1.1.1															
Me as dia meter for VLDL particles	-			1.1.1			PE2					•	_	1	1.	1			
Meanwhameter for LDL henicles	- A - 1	÷ (†	1. e		- 41 - 4	100				. 4	- A - 3		- 77	•	1	-			
Me as dia meter for HDL particles	- 6		*	+	1	104 			10	1	1	+		-	-	-			
Cholesterol				1.19															
To tal choleste tol	- 15 - 1	1 - 1	the the		51 T	018				10.1	-	•	100	- 81	- 50	8			
Taalo aadan xVLD.	4		1. 1.			1214	PE2		10 - N		-		-		11	ä.			
To tal choleste rol in LDL	*	• •	1 <u>11</u>							· · ·		•	<u>+</u>		+1	3			
Foral ond estero in FIDE				+										_		1			
Total choleste rol in HDL2	34	· <u></u>			141 ÷	31 <del>4</del>			#S.	÷. 57	Se 3			-	-	9			
Total crojestoro in HDL3	4				42 4				44		4	_			410				
Remnant choles terol	- X.	0.00	10 0.14		-	1004			80	10.01	+		-	- 30	10	9			
Ester fied chéroisea	1	1994 - S			. 1 1	1.11			***	1	-				100	1			
Free cholesterol		1814	-			1.1				1.11	-	+1	-		+	4			
Giycerkies and phospholipids	1		1	1.1.1	1.1					1.1	1				11	3			
To tal biglyce rides	÷.		1 1				PE2	PE3					-			1			
Thy yoanitaa ISMI Di	1	111	8 83	1 10		23	TE2	<b>T</b> 5	10	2.15	1				100	5			
Triglyce rides is LDL	- i -		· · ·									-	1	- 2	1	÷			
Trigisterides in LDL			8 S.	1.1.1	_ 2 1	10.4				1.14	12	1000	-		1	ê.			
Total phosphoglycerides	- 66	NO.	1.1		14.1	1.54				1.11	-	-			+				
Phosphologican issues other chaires	. H. 1	÷	÷ ÷		. t. t					• •	1			-	1.1	3			
Total cholines			*			1.1.4									10				
Sphingen year	4	1000	÷ •	+	41.4	11114			+ -		4				410	ē			
Apolipoproteina	- G	in an	10 K.		- (a) - 4	10.04			100		4.	<u>ан</u> та		- 14	-				
Appl poprote in A		_		L .							- 2	-		_					
A police protein 8	-		1	1.1	2.1	14			11	1 1		. 1		1	11	3			
Pario o' apolico poteir Bito apolico poteir A-l			5 52			ili <del>ti</del>	SPE2		11 E						+13				
A new April 1997 - A new April 1997 - 24	1				1				- 16	1			0		1.1	2			
	-10	-0.6	-0.2	0.2	0.6	1.0			-0.05	-0.03	3 .0	01 0.	01	0.03	. i	0.05			
	1.14			(99.8% CI)		14						Nbs (99.8			500 B				
			CO GIRLS	herate cel							200	ing baye	1,001						

Downloaded from https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab475/6311296 by Royal Library Aarhus University user on 05 July 2021

30



ĊĊ,

Downloaded from https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab475/6311296 by Royal Library Aarhus University user on 05 July 2021

31



Mean difference between groups

Difference in the change between groups


Lipoprotein subclasses Extremely large VLDL Very large VLDL Large VLCL Medium VLDL SmallVLD\_ Vey small VLDL ID. Large LOL NSONT LDL Small LDL Verylarge HDL Lage HOL Nedlam D. S mult HDL Lipoprotein particle size Mean diameter for VLDL partie Meanwiamater for LDL hanic Me un dia meter for HOL particle Cholesterol Total choieste rol Totalio presidenti n VLD. Total choiceste rol in LDL Joal dro estero in LDL Total choleste rol in HDL2 Total circlestore in HDL3 Remnant choies terol Exertication and the second Free choiesterol Glycerides and phospholipids Total triplyce rides Thy year itea in VLO Triglyce tides in LOL Trigistiendes in LDL Total phosphoglycerides Phosphelicyknolis, are alto Total cholines Cphingon year Apolipoproteins Appl poprotein A A polipo protein B

-

P.C.C.

Brownski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Voya lag, VLD.       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Voya lag, VLD.       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Brown VLD.       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Brown VLD.       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Brown VLD.       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL       Provinski gy, vil 3.       Provinski gy, vil 3.       Provinski gy, vil 3.         Sourt UL <td< th=""><th></th><th></th><th colspan="7">mean diserence between groups</th><th></th><th></th><th></th><th colspan="11">unterence in the change between groups</th></td<>			mean diserence between groups										unterence in the change between groups										
Dependent addutations         HT2         HT2           Very tity, NUL         HT2         HT2           Markan WUL         HT2         HT2           Markan Wul         HT2         HT2           Joint NUL         HT2         HT2           Start NUL         HT2         HT2           Start NUL         HT2         HT2           Start NUL         HT2         HT2           Start NUL         HT2         HT3           Start NUL         HT2         HT3           Start NUL         HT2         HT3           Start NUL         HT2         HT3           Start NUL         HT3         HT2           Start NUL         HT3         HT3           Start NUL         HT3         HT3           Start NUL         HT3         HT3			\$008	33	100	F 8338	-38					43	10	8.3	31	23	224			40	4		
Brown, Hg 2 013.       H72         Very ligh XLL       H72         Jarge RLL       H72         Smell XLD       H73         Smell XLD       H74         Smell XLD       H74 <tr< th=""><th>Lipoprotein subclasses</th><th>1</th><th>たらさ</th><th>2</th><th>- 51</th><th>1.000</th><th>100</th><th>100</th><th>5</th><th></th><th></th><th>12</th><th>125</th><th>X -</th><th>1</th><th>8</th><th>11.2</th><th></th><th></th><th>10</th><th>34</th><th></th><th></th></tr<>	Lipoprotein subclasses	1	たらさ	2	- 51	1.000	100	100	5			12	125	X -	1	8	11.2			10	34		
Lores et GL       ************************************	Extremely large VLDL	- 11	reat	- 10				1.12		HT2		3.5		-			-			100	-		
Media MUDL       I       I       I       I       III       IIII       IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Very large VLDL	100	\$383	12	- 22		-	100	÷	HT2			-	-	•	-	1	10		+3	1		
Media MUDL       I       I       I       I       III       IIII       IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Large VLCL		++			+				H Z		+ -								+			
Bink 10.0.	Medium VLDL	1	1 1	÷		-				HT2		10		-			1.17	1			-		
ID       Lage LDL       ID	SmalVLD_	13	10.1	12	133			100	5	HTZ		100	20	1-	•	5	2	135		11	5		
Laga LDL Notive JDL Simulation Simulati	Very small VLDL		1 1	- 2			_	1	-	HT2		1.1		а.,	<u>.                                    </u>		L		-				
Laga LDL Notive JDL Simulation Simulati	ID .				1.1		- 11								<u></u>	-	-						
Note: - DL Small DL Way Gap. HD Lags HD. Note: - D. Small HD.	Lane LDL	- 16	+10.5+	- 10				1.5						÷ .			L .	12		1			
Small LDL		1	1.1	.1	1	1. 1	Ť.	1.1	ŧ.			10	1	ä.,	Ť.	-				11	3		
bisso top-Pf1       Image is a particular of the state is a par		1	10.01	1	1			+111	-			11	1		1	<u> </u>		1.		1	1		
Laga Hill. Notor D. Smith D. Smith D. Smith D. Man daman for NUL professor Mana daman for NUL professor Total chalasa di In DL Total chalasa di In D		- +	++	-+-	12	+1	- + -	41111	÷			+1		4	+			10	_	+	1	HT9	
Notifier D.       Image: Second		1	1000	0.1	- 53	220+1014	1	1111	ţ			+1	1	1	+		2	20	- 16	11	2	niz	
Small HOL         HT2         HT2           Lipportion particle size         HT2         HT2         HT2         HT2           Mask dim and hVLD, patchs         HT2         HT2         HT2         HT2         HT2           Mask dim and hVLD, patchs         HT2         HT2         HT2         HT2         HT2         HT2         HT3           Chall chicks with         HT2         HT2         HT2         HT3         HT2         HT3           Total chicks with NUD, Total chicks wi	20.703.00.000		1.11			Γ.		100				1.1		÷	4		-	1.0	_				
Lipoprolain particle size Maar dia materior MUL particles Maar dia materior MUL particles Maar dia materior HOL particles Total debates and in LOL Total			* *	1	-			÷.,	÷			÷.	1	÷	÷.,						3		
Mass diamas for VLDL patisks       +       H12       H12       H12       H13         Mass diamas for VDL patisks       +       +       +       H12       H13         Choicsbool       + <td< td=""><td></td><td>4</td><td>****</td><td>-</td><td></td><td>+</td><td>·</td><td></td><td></td><td>HT2</td><td></td><td>+</td><td>-</td><td>+</td><td></td><td></td><td>0.1</td><td></td><td></td><td>14</td><td>_</td><td></td><td></td></td<>		4	****	-		+	·			HT2		+	-	+			0.1			14	_		
Neuroisciente for IDI seriess         HIZ         HI		19		- 2		1.5			÷.			1			÷.,	÷.					÷.		
Main dia mandra HDL patiska     HT2     HT3       Choleskowi     Totale declaskowi     HT2     HT3       Totale declaskowi     HT2     HT2     HT3       Totale declaskowi     HT2     HT3     HT3       Totale declaskowi     HT4     HT3     HT4       Totale declaskowi     HT5     HT3     HT4       Totale declaskowi     HT2     HT3     HT4       Totale declaskowi     HT2     HT3     HT4       System AHDL3     HT4     HT5     HT4       Faxe fielder declaskowi     HT5     HT3     HT4       System AHDL3     HT5     HT3     HT4       Totale declaskowi     HT5     HT5     HT5       Totale declaskowi     HT7     HT5     HT5		1	1.1	- 1	1	100	•	1	<u>.</u>	HT2		- 1	1.1	1		1	- 1	12	2	13	S		
Choicesterol       HT2         Total chalasandi       HT2         Total chalasandi sLDL       HT2         Fase fieldcrassen       HT2         Fase fieldcrassen       HT2         Total chalasandi sLDL       HT2         Total chalas		14	1.1.1	- 14	1.	1203	14						10	Χ.	4	£.,		•		11	G		
Cholestered Total cholestered		- 2	-	- 10	•	1.1.1	- 20					1	1	*	*	<u>*</u> :	-	•			1	HI2	HT3
Mark     M2       Total c academ ani ALD.     Image: Academ ani ALD.       Total chalactar dia IDL     Image: Academ ani ALD.       Face Academ and Academ																							
Table declarational (LDL)       Image: Constraint of the Const		- 90	¥ - ¥	- 96			- 20 m	+	÷					¥ .		•				+3	9		
103 010 0101       Image: 100 0100 0100000000000000000000000000	Tatalo ataskao nVLD.	-4	41.114	4				41134		HT2		+		4.17	41	÷	-			411			
Total childs with PD12     +     +     +       Total childs with     +     +     +       Rama the black with     +     +     +       Face fields around     +     +     +       Face childs ke with     +     +     +       Gyter Kes and phospholiptids     +     +     +       Total childs a LOL     +     +     +       Total childs a LOL     +     +     +       Total childs a LOL     +     +     +       Trig yzerides a LOL     +     +     +       Reinholdyke nise are ofter christer     +     +     +       Applipportex h     +     +     +     +       Applipportex h     +     +     +     +       -10     -06	To tal choleste rol in LDL	1	t E t	- 20	-	-	1.00					82	100	1.		•				10	1		
Total choice and       +       HT2         Remarks heles and       +       HT2         Face choices and       +       +         Face choices and phospholipids       +       +         Total bigles ities       +       +         Total bigles ities and biolog       +       +         Total bigles ities       +       +         Provide state       +       +         Total bigles ities       +       +         Choice bigles       +       +         Choice bigles       +       +         Applipporte ha       +       +         Applipporte hA       +       +         Applipporte hA       +       +         -10       -0.6       -0.2       0.6       +	Local dro extero in LDL	34.5	1004	- 10		- t	34.1	1133	· · · ·			34-2	101	a :	4	*		21/8		10	-		
Remark to ble & and     HT2       Ever field constant     +       Field constant     +       Gyperkies and phospholipids     +       Traubibly to the     HT2       Tray set des hills     +       Prove the set of the set	Total choleste rol in HDL2	10	11894	-			-	100	÷				103	8	÷.	-	-	-	-	+3			
Remarks held     H12       Exer field crossent     H12       Fise d helds held     H12       Gyterikes and phosphelpids     H12       Total digives ities     H12       Trigizerikes and phosphelpids     H12       Trigizerikes is LDL     H12       Trigizerikes all LDL     H12       Filesphray     H12       Filesphray     H12       Applipoproteins     H12       Applipoproteins     H12       -10     0.6       -10     0.6       -10     0.6       <	Total circlestore in HDL3				-										. •		•	-18 I					
Fine choice ind         HT2         HT3         HT2         HT3           Traysenities ovid 3         HT2         HT3         HT3         HT3           Traysenities ovid 3         HT2         HT3         HT3         HT3           Traysenities ovid 3         HT3         HT3         HT3         HT3           Traisplexities ovid 10_         HT3         HT3         HT3         HT3           Traisplexities ovid 10_         HT3         HT3         HT3         HT3           Applipaproteins         HT3         HT3         HT3         HT3         HT3           Applipaproteins         HT3         HT3         HT3         HT3         HT3         HT3           Tube ovid 3         HT3         HT3         HT3         HT3         HT3         HT3	Remnant choles tarol	1	1 1	÷.						HT2					-	•		1					
Gyperikes and phospholipids         HT2         HT3         HT2         HT3           Try systeks a MUS         HT2         HT3         HT3         HT3           Try systeks a MUS         HT2         HT3         HT3         HT3           Try systeks a MUS         HT3         HT3         HT3         HT3           Try systeks a MUS         HT3         HT3         HT3         HT3           Total phospholycerides         HT3         HT3         HT3         HT3           Total phospholycerides         HT3         HT3         HT3         HT3           Applipaproteins         HT3         HT3         HT3         HT3           Applipaproteins         HT3         HT3         HT3         HT3           Tube dial diales         HT3         HT3         HT3         HT3           Applipaproteins         HT3         HT3         HT3         HT3           Tube diale dialogic dial 3 is sidian diale diale         HT3	Exer Gol croissient	1	1001	1	1.1		1	1000	5			1.5	1	1	1			35		10	5		
Tabilitybenities     HT2     HT3     HT2       Trysterities +012     HT2     HT2     HT2       Trysterities +10_     HT2     HT2     HT2       Trysterities +10_     HT2     HT2     HT2       Trail phosphoglyceides     HT2     HT2     HT2       Total phosphoglyceides     HT2     HT2     HT2       Applipoproteins     HT2     HT2     HT2       Total chaines     HT2     HT2     HT2	Free cholesterol	- i -	1.1	- 2				1	2			- 2	-	1.1	-		-			-	1		
Tabilitybenities     HT2     HT3     HT2       Trysterities +012     HT2     HT2     HT2       Trysterities +10_     HT2     HT2     HT2       Trysterities +10_     HT2     HT2     HT2       Trail phosphoglyceides     HT2     HT2     HT2       Total phosphoglyceides     HT2     HT2     HT2       Applipoproteins     HT2     HT2     HT2       Total chaines     HT2     HT2     HT2	Givcerkies and phospholipids		A.1.1.A			100			ŧ.					4		6	-			43			
Projective of 3     HT2       Triggenities is LDL     IT2       Triggenities is an obstation     IT2       Triggenities is an obstation     IT2       Applipoproteins     IT2       Applipoproteins     IT2       Applipoproteins     IT2       Applipoproteins     IT2       IT2     IT2       IT2     IT2		- 040	410.14	10					+	HT2	HT3	100				* .	1.1					HI2	
Tiglyce idea in LOL     1172       Tig yzerides in LOL     1172       Total chalmes     1172       Sphrophysin     1172       Apelipoproteins     1172       Apelipoproteins     1172       Apelipoproteins     1172       Apelipoproteins     1172       1172     1172		1	1.1	Ť		1			i.			11		-	۰.	-		100		÷.	3	HT2	
Trg verifies n1D.     IT2       Total phosphoglycelides     IT2       Plosphoglycelides     IT2       Total cholines     IT2       Total cholines     IT2       Apolipoproteins     IT2       Apolipoproteins     IT2       Apolipoproteins     IT2       Image: Instruction of the image of t		1	+1 ++	1	-			1	+				10	1	+0.5	-		1.2		1	1		
Tatal plasphoglyceides Plasphoglyceides Plasphoglyceides Plasphoglyceides Sphroparosina Apolipoprosina Apolipoprosina Apolipoprosina Polipoprosina Apolipoprosina Plasphoglyceides Pl	· · · · · · · · · · · · · · · · · · ·	- 41	41014	- 4	-	+ +		41113	÷	1172		+ -		÷.	÷	<u>_</u>	-			410	-		
Pleachais, sea obsratelises Total cholines Sphryparyseit Apolipoproteins Apolipoproteins Apolipoproteins Apolipoproteins HT2 HT2 HT2 HT2 HT2 HT2 HT2 HT2		1	1000	7		+1500		1	t			+11			_	<u>.</u>				1			
Tableholmes (phryonyset) Apolipoproteins Apolipoprotei	1.1 (1.1 (1.1 (1.1 (1.1 (1.1 (1.1 (1.1		1.1			-	10040		ł			10		ŝ.	<u> </u>	-	_	1		1			
Sphrypmysin         - <td< td=""><td></td><td>-</td><td>1.1</td><td>- 5</td><td></td><td>- + - +</td><td></td><td>1.1</td><td>ł</td><td></td><td></td><td></td><td></td><td>1</td><td>÷</td><td>1.5</td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td></td<>		-	1.1	- 5		- + - +		1.1	ł					1	÷	1.5					1		
Apolipoproteins #polipoproteins Apolip			+1+	-	- 21			-	-			+		-	4	+1111			24	-	4		
Apolopoposin A Apolopoposin B Reside a social constrained and a socia						10000										100							
Apalip provin B Relation's of a station static of the form of the	철물 해외 전쟁에 집에 있는 것이 없는 것이 같은 것이 없다.	1	1.1	- 1	10	1	1	1	1			- 24	1	1	1	2.1		1	1	1			
Psilon's olicovet-i 3 msodicovet-i 4 H7 H7		1.	1.1.1				14	410.1	1					¥	. 7			10		11	14		
		1	+ +	1			-	*					10	1	in.	-		1	1	1	1		
-10 -0.6 -0.2 0.2 0.6 1.0 -0.05 -0.03 -0.01 0.01 0.03 0.05	Psito anapolico veter 15 to spelice o stein A-l			-	1	1		-		HZ				1									
			- 1	12	1	· · ·	-	- 1	1			0.000		1	110		-		1		1		
SD units (99.8% CI) SD units (99.8% CI)		-10	-0.6					1	D			-0.05	-(						0.03	§	0.05		
				S	Dianita	(99.8% CI)									SD I	nis ș	99.8%	CI)					

Downloaded from https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab475/6311296 by Royal Library Aarhus University user on 05 July 2021



CCk

Downloaded from https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab475/6311296 by Royal Library Aarhus University user on 05 July 2021

33